Nifty
Sensex
:
:
9915.25
32028.89
41.95 (0.42%)
124.49 (0.39%)

Pharmaceuticals & Drugs

Rating :
37/99

BSE: 532296 | NSE: GLENMARK

696.30
-12.00 (-1.69%)
21-Jul-2017 | 3:48PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 707.60
  • 709.95
  • 695.15
  • 708.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  • 274577
  • 1911.88
  • 994.00
  • 600.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 19,949.43
  • 17.99
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 23,068.29
  • 0.28%
  • 4.44

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.5%
  • 2.98%
  • 8.55%
  • FII
  • DII
  • Others
  • 2.72%
  • 3.33%
  • 35.92%

Chart

Price | P:E | P:BV | EV:EBITDA

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Var%
Dec 16
Dec 15
Var%
Sep 16
Sep 15
Var%
Jun 16
Jun 15
Var%
Net Sales
2,457.18
2,281.25
7.71%
2,535.01
1,756.37
44.33%
2,224.11
1,874.64
18.64%
1,943.05
1,647.74
17.92%
Expenses
2,013.34
1,978.62
1.75%
1,769.98
1,386.60
27.65%
1,775.34
1,472.75
20.55%
1,563.98
1,288.16
21.41%
EBITDA
443.84
302.63
46.66%
765.02
369.76
106.90%
448.77
401.88
11.67%
379.07
359.58
5.42%
EBIDTM
18.06%
13.27%
30.18%
21.05%
20.18%
21.44%
19.51%
21.82%
Other Income
-51.29
11.69
-
14.57
2.14
580.84%
-1.84
0.80
-
75.92
5.37
1,313.78%
Interest
69.67
47.50
46.67%
61.74
46.85
31.78%
62.87
42.62
47.51%
43.04
41.91
2.70%
Depreciation
68.90
62.78
9.75%
62.53
55.85
11.96%
68.70
63.38
8.39%
64.23
69.74
-7.90%
PBT
173.03
204.04
-15.20%
655.33
269.19
143.45%
315.36
296.68
6.30%
347.71
253.29
37.28%
Tax
-10.73
32.75
-
178.23
99.25
79.58%
91.77
96.25
-4.65%
120.93
75.06
61.11%
PAT
183.76
171.29
7.28%
477.10
169.94
180.75%
223.58
200.44
11.54%
226.78
178.23
27.24%
PATM
7.48%
7.51%
18.82%
9.68%
10.05%
10.69%
11.67%
10.82%
EPS
6.51
6.08
7.07%
16.91
6.02
180.90%
7.92
7.10
11.55%
8.04
6.32
27.22%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Net Sales
7,719.74
6,680.94
5,944.95
4,969.14
4,020.64
2,949.07
2,480.46
2,086.48
1,975.71
1,222.04
Net Sales Growth
15.55%
12.38%
19.64%
23.59%
36.34%
18.89%
18.88%
5.61%
61.67%
 
Cost Of Goods Sold
1,927.78
1,538.25
1,785.62
1,584.70
1,291.00
951.07
784.28
658.07
472.22
316.42
Gross Profit
5,791.97
5,142.69
4,159.33
3,384.44
2,729.65
1,998.00
1,696.18
1,428.41
1,503.48
905.62
GP Margin
75.03%
76.98%
69.96%
68.11%
67.89%
67.75%
68.38%
68.46%
76.10%
74.11%
Total Expenditure
6,285.89
5,466.62
4,854.17
3,953.86
3,306.28
2,356.82
1,860.89
1,631.50
1,175.18
795.76
Power & Fuel Cost
120.47
109.11
93.50
80.13
0.00
0.00
31.86
25.55
19.48
16.58
% Of Sales
1.56%
1.63%
1.57%
1.61%
0%
0%
1.28%
1.22%
0.99%
1.36%
Employee Cost
1,377.23
1,212.61
1,026.15
782.95
628.89
510.17
289.95
272.34
173.54
121.46
% Of Sales
17.84%
18.15%
17.26%
15.76%
15.64%
17.30%
11.69%
13.05%
8.78%
9.94%
Manufacturing Exp.
1,305.43
1,323.66
336.59
272.53
54.40
40.76
142.80
156.13
154.22
83.41
% Of Sales
16.91%
19.81%
5.66%
5.48%
1.35%
1.38%
5.76%
7.48%
7.81%
6.83%
General & Admin Exp.
285.96
253.29
859.67
678.94
1,331.99
854.82
268.51
258.24
175.40
140.00
% Of Sales
3.70%
3.79%
14.46%
13.66%
33.13%
28.99%
10.83%
12.38%
8.88%
11.46%
Selling & Distn. Exp.
1,257.65
991.23
524.25
521.00
0.00
0.00
310.32
254.38
171.85
113.26
% Of Sales
16.29%
14.84%
8.82%
10.48%
0%
0%
12.51%
12.19%
8.70%
9.27%
Miscellaneous Exp.
11.36
38.48
228.40
33.61
0.00
0.00
33.15
6.79
8.47
113.26
% Of Sales
0.15%
0.58%
3.84%
0.68%
0%
0%
1.34%
0.33%
0.43%
0.38%
EBITDA
1,433.85
1,214.32
1,090.78
1,015.28
714.36
592.25
619.57
454.98
800.53
426.28
EBITDA Margin
18.57%
18.18%
18.35%
20.43%
17.77%
20.08%
24.98%
21.81%
40.52%
34.88%
Other Income
20.00
6.88
11.48
10.75
18.17
144.41
50.45
179.26
53.69
17.12
Interest
178.88
190.15
188.59
160.01
146.57
160.46
165.50
145.72
71.04
39.83
Depreciation
251.76
300.41
216.79
127.01
97.88
94.68
120.61
102.68
71.68
42.26
PBT
1,023.21
730.63
696.88
739.00
488.09
481.54
383.90
385.84
711.50
361.32
Tax
303.30
334.07
151.27
110.72
23.78
23.70
52.87
75.41
79.39
51.26
Tax Rate
29.64%
61.46%
21.71%
14.98%
4.87%
4.92%
13.77%
28.04%
11.16%
14.19%
PAT
720.10
209.54
542.27
620.03
460.35
453.20
324.47
191.66
632.13
310.06
PAT before Minority Interest
719.91
209.47
545.60
628.29
464.31
457.83
331.03
193.47
632.11
310.06
Minority Interest
0.19
0.07
-3.33
-8.26
-3.96
-4.63
-6.56
-1.81
0.02
0.00
PAT Margin
9.33%
3.14%
9.12%
12.48%
11.45%
15.37%
13.08%
9.19%
32.00%
25.37%
PAT Growth
243.66%
-61.36%
-12.54%
34.69%
1.58%
39.67%
69.29%
-69.68%
103.87%
 
Unadjusted EPS
25.65
7.72
20.01
22.91
17.03
16.78
12.40
7.70
25.80
12.99

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Shareholder's Funds
3,056.44
1,783.49
2,983.28
2,763.03
2,401.63
2,037.24
2,355.23
1,598.16
1,517.87
686.37
Share Capital
28.22
27.13
27.12
27.09
27.05
27.03
26.98
25.05
24.87
24.01
Total Reserves
3,028.22
1,756.36
2,956.16
2,735.94
2,374.58
2,010.21
2,328.25
1,573.10
1,493.00
662.35
Non-Current Liabilities
2,538.92
2,749.09
1,966.58
1,625.13
1,137.64
519.01
1,940.41
2,151.27
1,085.49
1,008.71
Secured Loans
0.00
0.00
2,428.66
1,920.30
1,312.47
617.07
241.41
382.65
196.13
174.93
Unsecured Loans
2,487.30
2,574.38
0.00
0.00
0.00
0.00
1,627.98
1,711.69
794.81
761.78
Long Term Provisions
0.00
0.00
0.00
0.00
14.58
6.90
0.00
0.00
0.00
0.00
Current Liabilities
4,067.24
3,776.71
2,949.17
2,201.39
1,901.74
2,259.06
518.62
456.33
320.72
239.51
Trade Payables
1,940.79
1,948.04
1,362.58
1,036.94
788.83
657.41
379.27
343.48
230.79
160.15
Other Current Liabilities
1,137.01
1,264.30
973.31
763.41
414.83
109.80
119.38
96.41
72.17
72.18
Short Term Borrowings
787.42
347.60
353.32
367.82
687.46
1,480.23
0.00
0.00
0.00
0.00
Short Term Provisions
202.03
216.78
259.95
33.22
10.63
11.62
19.97
16.44
17.76
7.18
Total Liabilities
9,662.30
8,309.10
7,912.31
6,613.91
5,466.01
4,842.01
4,827.27
4,208.92
2,925.56
1,934.59
Net Block
2,573.86
2,015.38
2,889.66
2,406.26
2,237.30
2,066.62
1,787.31
1,566.24
918.51
592.86
Gross Block
4,300.54
3,495.47
3,632.62
2,934.90
2,650.96
2,383.39
2,175.54
1,838.58
1,124.10
709.37
Accumulated Depreciation
1,726.68
1,480.09
742.96
528.63
413.66
316.77
388.23
272.33
205.59
116.51
Non Current Assets
3,751.25
2,978.04
3,149.61
2,887.10
2,518.85
2,243.24
2,406.20
2,129.78
1,274.56
829.15
Capital Work in Progress
542.79
477.13
206.24
422.31
248.33
145.70
600.77
545.41
337.23
217.57
Non Current Investment
17.20
17.12
0.00
0.00
0.00
0.00
18.12
18.12
18.82
18.72
Long Term Loans & Adv.
617.24
468.16
33.39
36.52
0.00
0.00
0.00
0.00
0.00
0.00
Other Non Current Assets
0.16
0.27
20.33
22.00
33.23
30.92
0.00
0.00
0.00
0.00
Current Assets
5,911.05
5,331.06
4,762.69
3,726.81
2,947.15
2,598.77
2,421.07
2,079.14
1,651.00
1,105.43
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
1,567.76
1,269.04
932.88
843.53
787.67
807.01
708.46
630.23
400.74
269.71
Sundry Debtors
2,492.65
2,511.76
2,156.34
1,640.05
1,243.61
1,130.81
1,078.28
955.34
806.85
565.97
Cash & Bank
869.24
775.88
800.67
607.31
321.92
195.83
107.02
71.48
156.51
105.75
Other Current Assets
981.41
31.44
104.37
95.88
593.95
465.11
527.31
422.09
286.90
164.00
Short Term Loans & Adv.
810.30
742.94
768.44
540.03
518.90
322.39
527.31
422.09
286.90
164.00
Net Current Assets
1,843.81
1,554.35
1,813.53
1,525.42
1,045.41
339.71
1,902.45
1,622.81
1,330.28
865.92
Total Assets
9,662.30
8,309.10
7,912.30
6,613.91
5,466.00
4,842.01
4,827.27
4,208.92
2,925.56
1,934.58

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Cash From Operating Activity
344.85
481.68
853.73
647.93
804.39
930.58
352.40
15.91
371.78
93.24
PBT
1,023.21
543.54
696.88
739.00
488.09
481.55
383.90
268.88
711.50
361.32
Adjustment
407.55
522.76
709.78
342.45
484.05
189.65
265.26
274.15
133.39
85.89
Changes in Working Capital
-607.71
-266.82
-290.07
-268.49
-34.79
353.13
-209.36
-387.66
-384.56
-326.27
Cash after chg. in Working capital
823.05
799.49
1,116.58
812.96
937.35
1,024.34
439.80
155.37
460.33
120.94
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-478.20
-317.81
-262.86
-165.03
-132.96
-93.75
-87.40
-139.46
-88.55
-27.70
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-880.17
-540.04
-368.10
-464.06
-277.79
-367.27
-386.91
-950.16
-509.62
-268.78
Net Fixed Assets
-286.93
-1,354.84
-112.12
-178.05
-54.88
-40.77
-52.58
406.38
-188.35
-144.44
Net Investments
-198.90
-250.28
-114.91
-211.06
-42.02
-48.33
-755.29
-40.93
-57.60
-95.54
Others
-394.34
1,065.08
-141.07
-74.95
-180.89
-278.17
420.96
-1,315.61
-263.67
-28.80
Cash from Financing Activity
698.60
199.22
-98.02
195.24
-361.39
-435.61
70.05
849.23
188.58
175.70
Net Cash Inflow / Outflow
163.27
140.86
387.61
379.11
165.21
127.70
35.54
-85.02
50.75
0.16
Opening Cash & Equivalents
763.74
794.80
605.18
320.08
194.87
103.58
71.48
156.51
105.75
105.60
Closing Cash & Equivalent
857.12
763.74
794.80
605.18
320.08
194.87
107.02
71.48
156.51
105.75

Financial Ratios

Consolidated /

Standalone
Description
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Book Value (Rs.)
108.32
65.74
109.99
102.01
88.77
75.38
87.28
63.79
61.03
28.58
ROA
8.01%
2.58%
7.51%
10.40%
9.01%
9.47%
7.33%
5.42%
26.01%
18.92%
ROE
29.75%
8.79%
18.99%
24.33%
20.92%
20.85%
16.75%
12.42%
57.35%
58.62%
ROCE
19.04%
12.40%
15.04%
17.67%
14.44%
15.34%
13.88%
13.37%
37.88%
29.17%
Fixed Asset Turnover
2.00
1.90
1.83
1.79
1.60
1.29
1.25
1.43
2.19
2.02
Receivable days
116.95
125.97
115.37
104.99
107.78
136.71
148.42
151.98
124.70
138.17
Inventory Days
66.29
59.42
53.99
59.39
72.38
93.78
97.70
88.92
60.90
62.30
Payable days
109.46
95.22
83.15
68.48
108.47
106.73
68.48
62.10
61.26
65.28
Cash Conversion Cycle
73.78
90.17
86.21
95.91
71.69
123.76
177.63
178.80
124.34
135.19
Total Debt/Equity
1.30
2.13
1.10
1.00
0.93
1.03
0.79
1.31
0.65
1.36
Interest Cover
6.72
3.86
4.70
5.62
4.33
4.00
3.32
2.85
11.02
10.07

News Update


  • Glenmark Pharmaceuticals enters into exclusive agreement with Cyndea Pharma
    19th Jul 2017, 08:51 AM

    The development, license, manufacture and commercial supply agreement is for Generic Soft-Gelatin Capsule Drug Products

    Read More
  • Glenmark receives USFDA approval for generic version of Azor Tablets
    7th Jul 2017, 09:05 AM

    The Azor Tablets market achieved annual sales of approximately $211.6 million for 12 month period ending May 2017

    Read More
  • Glenmark receives final approval by MHRA for Maloff Protect
    4th Jul 2017, 09:07 AM

    Maloff Protect (250mg/100mg atovaquone/proguanil film-coated tablets) is the first OTC approval granted by the MHRA

    Read More
  • Glenmark receives ANDA approval for Indomethacin Extended-Release Capsules
    27th Jun 2017, 09:06 AM

    Indomethacin Extended-Release Capsules USP, 75 mg is the generic version of Indocin SR Extended-Release Capsules, 75 mg of Iroko Pharmaceuticals LLC

    Read More
  • Glenmark receives tentative ANDA approval for generic Vesicare Tablets
    22nd Jun 2017, 09:02 AM

    The Vesicare Tablets, 5 mg and 10 mg market achieved annual sales of approximately $1.1 billion

    Read More
  • Glenmark enters into licensing agreement with APC Therapeutics
    21st Jun 2017, 09:03 AM

    Glenmark will license the product from APC Therapeutics, and manage all clinical development including regulatory filings and commercialization worldwide

    Read More
  • Glenmark Pharma gets USFDA’s nod for Saxagliptin Tablets
    14th Jun 2017, 10:09 AM

    The company’s current portfolio consists of 117 products authorized for distribution in the U.S. marketplace

    Read More
  • Glenmark receives final approval for generic version of Strattera Capsules
    31st May 2017, 09:00 AM

    The Strattera Capsules, 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg market achieved annual sales of approximately $1.1 billion

    Read More
  • Glenmark receives final approval for generic version of Bystolic Tablets
    29th May 2017, 09:01 AM

    The Bystolic Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg market1 achieved annual sales of approximately $1.0 billion

    Read More
  • Glenmark receives final approval from USFDA for generic version of Benicar Tablets
    26th May 2017, 09:20 AM

    The Benicar Tablets, 5 mg, 20 mg and 40 mg market achieved annual sales of approximately $950.0 million

    Read More
  • Glenmark Pharmaceuticals to initiate clinical study for GBR 1342
    16th May 2017, 09:19 AM

    USFDA cleared the company’s IND application to initiate a Phase 1 study of GBR 1342

    Read More
  • Glenmark Pharma - Quarterly Results
    11th May 2017, 12:00 AM

    Read More
  • Glenmark Pharmaceuticals initiates clinical investigation for GBR 310
    25th Apr 2017, 09:19 AM

    GBR 310 is a proposed biosimilar, which will assess its pharmacokinetics in comparison to XOLAIR (omalizumab) in healthy adult volunteers between 18 - 65 years of age

    Read More
  • Glenmark receives tentative approval for generic version of Pradaxa Capsules
    19th Apr 2017, 08:50 AM

    The Pradaxa Capsules, 75 mg, 110 mg and 150 mg market achieved annual sales of approximately $913 million

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.